Braidwell LP Acquires New Holdings in Adlai Nortye Ltd. Sponsored ADR $ANL

Braidwell LP bought a new stake in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 795,214 shares of the company’s stock, valued at approximately $9,145,000. Braidwell LP owned about 1.99% of Adlai Nortye at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. SmartHarvest Portfolios LLC boosted its holdings in shares of Adlai Nortye by 8.5% in the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after buying an additional 1,279 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Adlai Nortye in the 1st quarter worth approximately $457,000. ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye during the 1st quarter worth approximately $816,000. Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye during the 1st quarter worth approximately $1,140,000. Finally, Boone Capital Management LLC purchased a new stake in Adlai Nortye during the second quarter valued at approximately $2,971,000. 35.21% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Cantor Fitzgerald began coverage on shares of Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. JonesTrading began coverage on Adlai Nortye in a report on Thursday, May 14th. They set a “buy” rating and a $22.00 price objective for the company. Oppenheimer initiated coverage on Adlai Nortye in a research note on Thursday, May 28th. They set an “outperform” rating and a $32.00 target price on the stock. Finally, Wall Street Zen raised Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $24.25.

Adlai Nortye Trading Up 1.6%

NASDAQ:ANL opened at $13.85 on Thursday. Adlai Nortye Ltd. Sponsored ADR has a twelve month low of $0.88 and a twelve month high of $17.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. The company’s 50 day moving average is $12.36 and its two-hundred day moving average is $11.31.

Insider Activity

In other news, CFO Xiaofeng Ye sold 6,000 shares of Adlai Nortye stock in a transaction on Monday, August 24th. The shares were sold at an average price of $13.98, for a total transaction of $83,880.00. Following the completion of the sale, the chief financial officer directly owned 153,424 shares in the company, valued at approximately $2,144,867.52. The trade was a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.